Medpace Holdings, Inc. (NASDAQ:MEDP) Expected to Post Q4 2024 Earnings of $2.86 Per Share

Medpace Holdings, Inc. (NASDAQ:MEDP) – Research analysts at William Blair reduced their Q4 2024 earnings per share (EPS) estimates for Medpace in a report released on Wednesday, July 24th. William Blair analyst M. Smock now forecasts that the company will earn $2.86 per share for the quarter, down from their previous estimate of $2.88. William Blair has a “Outperform” rating on the stock. The consensus estimate for Medpace’s current full-year earnings is $11.59 per share. William Blair also issued estimates for Medpace’s Q3 2025 earnings at $3.23 EPS, Q4 2025 earnings at $3.40 EPS and FY2025 earnings at $13.14 EPS.

Other equities research analysts also recently issued research reports about the company. TD Cowen cut their price target on Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a report on Wednesday. Mizuho started coverage on shares of Medpace in a report on Tuesday, May 28th. They set a “buy” rating and a $435.00 target price for the company. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and raised their price objective for the stock from $340.00 to $450.00 in a research report on Tuesday, April 23rd. Deutsche Bank Aktiengesellschaft lowered their target price on Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research note on Wednesday. Finally, Guggenheim decreased their price objective on Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a report on Wednesday. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Medpace presently has a consensus rating of “Moderate Buy” and an average target price of $424.14.

Medpace Stock Down 0.4 %

MEDP opened at $380.50 on Friday. Medpace has a 12-month low of $227.21 and a 12-month high of $459.77. The business has a 50 day moving average of $404.55 and a 200-day moving average of $381.65. The stock has a market cap of $11.80 billion, a price-to-earnings ratio of 38.79, a PEG ratio of 1.84 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.54 by $0.21. The business had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. Medpace had a net margin of 16.74% and a return on equity of 55.14%. Medpace’s revenue was up 14.6% on a year-over-year basis. During the same period last year, the business posted $1.93 EPS.

Insider Buying and Selling

In other news, CEO August J. Troendle sold 15,102 shares of the business’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $400.69, for a total value of $6,051,220.38. Following the completion of the transaction, the chief executive officer now directly owns 791,541 shares in the company, valued at approximately $317,162,563.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO August J. Troendle sold 15,102 shares of the business’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the completion of the transaction, the chief executive officer now owns 791,541 shares of the company’s stock, valued at approximately $317,162,563.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO August J. Troendle sold 5,695 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $395.49, for a total value of $2,252,315.55. Following the sale, the chief executive officer now owns 654,656 shares of the company’s stock, valued at $258,909,901.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,621 shares of company stock worth $11,816,852. Company insiders own 20.30% of the company’s stock.

Hedge Funds Weigh In On Medpace

Institutional investors have recently added to or reduced their stakes in the stock. Arcadia Investment Management Corp MI grew its stake in shares of Medpace by 40.3% during the first quarter. Arcadia Investment Management Corp MI now owns 101 shares of the company’s stock worth $41,000 after buying an additional 29 shares during the last quarter. Miller Howard Investments Inc. NY increased its holdings in Medpace by 1.3% in the 4th quarter. Miller Howard Investments Inc. NY now owns 3,075 shares of the company’s stock worth $943,000 after purchasing an additional 39 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Medpace by 5.3% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 781 shares of the company’s stock worth $316,000 after purchasing an additional 39 shares during the last quarter. Coldstream Capital Management Inc. grew its holdings in Medpace by 5.0% during the 4th quarter. Coldstream Capital Management Inc. now owns 954 shares of the company’s stock worth $292,000 after acquiring an additional 45 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in Medpace by 43.3% in the first quarter. GAMMA Investing LLC now owns 149 shares of the company’s stock valued at $60,000 after purchasing an additional 45 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.